PNV-001
PNV-001, also known as deuterated basmisanil, is a highly selective α 5 subunit-containing GABA A receptor negative allosteric modulator which is under investigation for the treatment of treatment-resistant depression and suicidal ideation.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
PNV-001, also known as deuterated basmisanil, is a highly selective α 5 subunit-containing GABA A receptor negative allosteric modulator which is under investigation for the treatment of treatment-resistant depression and suicidal ideation. It is a deuterated analogue of basmisanil with improved pharmacokinetics and metabolic stability.
The drug's half-life is 5.5-fold longer than that of basmisanil in human liver microsomes in vitro. It produces rapid and persistent antidepressant-like effects in animals.
PNV-001 and related drugs are said to lack the undesirable central effects of hallucinogens like ketamine and serotonergic psychedelics and of non-subunit-selective GABA A receptor negative allosteric modulators like flumazenil. It is being developed by ProNovo Therapeutics. As of September 2023, it is in the preclinical research stage of development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372044750 under CC BY-SA 4.0; modifications have been made.